dc.contributorUniversidade Federal de Juiz de Fora (UFJF)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorInstitut de Chimie des Substances Naturelles
dc.date.accessioned2014-05-27T11:29:05Z
dc.date.accessioned2022-10-05T18:49:36Z
dc.date.available2014-05-27T11:29:05Z
dc.date.available2022-10-05T18:49:36Z
dc.date.created2014-05-27T11:29:05Z
dc.date.issued2013-05-01
dc.identifierMedicinal Chemistry, v. 9, n. 3, p. 351-359, 2013.
dc.identifier1573-4064
dc.identifier1875-6638
dc.identifierhttp://hdl.handle.net/11449/75302
dc.identifier10.2174/1573406411309030005
dc.identifierWOS:000317910800004
dc.identifier2-s2.0-84877931409
dc.identifier2114570774349859
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3924239
dc.description.abstractThis paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the first and second line drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction. © 2013 Bentham Science Publishers.
dc.languageeng
dc.relationMedicinal Chemistry
dc.relation2.631
dc.relation0,372
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAntibacterial
dc.subjectAntileishmanial
dc.subjectBiological activities
dc.subjectCytotoxicity
dc.subjectHexahydropyrimidine derivatives
dc.subjectImidazolidine
dc.subjectSynthesis
dc.subjectX-ray crystallography
dc.subjectantiinfective agent
dc.subjectantileishmanial agent
dc.subjectheterocyclic compound
dc.subjecthexahydropyrimidine derivative
dc.subjectimidazolidine derivative
dc.subjectunclassified drug
dc.subjectanimal cell
dc.subjectantibacterial activity
dc.subjectbiological activity
dc.subjectcontrolled study
dc.subjectcrystal structure
dc.subjectcytotoxicity
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectEscherichia coli
dc.subjectin vitro study
dc.subjectLeishmania
dc.subjectLeishmania major
dc.subjectminimum inhibitory concentration
dc.subjectmouse
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectStaphylococcus aureus
dc.subjectX ray crystallography
dc.subjectX ray diffraction
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectAntiparasitic Agents
dc.subjectBacteria
dc.subjectCells, Cultured
dc.subjectCrystallography, X-Ray
dc.subjectHumans
dc.subjectImidazolidines
dc.subjectMice
dc.subjectMicrobial Viability
dc.subjectModels, Molecular
dc.subjectMolecular Structure
dc.subjectPyrimidines
dc.titleSynthesis, cytotoxicity, antibacterial and antileishmanial activities of imidazolidine and hexahydropyrimidine derivatives
dc.typeArtigo


Este ítem pertenece a la siguiente institución